Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations | Zendy

Brian T. Tsuji | Zendy; Jürgen B. Bulitta | Zendy; Tanya M. Brown | Zendy; Alan Forrest | Zendy; Pamela Kelchlin | Zendy; Patricia N. Holden | Zendy; Charles A. Peloquin | Zendy; Laura A. Skerlos | Zendy; David B. Hanna | Zendy

Open Access

Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations

Author(s) -

Brian T. Tsuji,

Jürgen B. Bulitta,

Tanya M. Brown,

Alan Forrest,

Pamela Kelchlin,

Patricia N. Holden,

Charles A. Peloquin,

Laura A. Skerlos,

David B. Hanna

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks201

Subject(s) - linezolid , enterococcus faecalis , microbiology and biotechnology , vancomycin , enterococcus , pharmacodynamics , antibiotics , minimum inhibitory concentration , biology , pharmacokinetics , medicine , staphylococcus aureus , bacteria , pharmacology , genetics

Vancomycin-resistant enterococci (VRE) have emerged as an important nosocomial pathogen in medical centres worldwide. This study evaluated the impact of front-loading of linezolid on bacterial killing and suppression of resistance against VRE strains with defined genetic mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research